|
Sarilumab for moderate to severe active rheumatoid arthritis |
NIHR HSRIC |
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Sarilumab for moderate to severe active rheumatoid arthritis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Sarilumab is intended to be used as a first and second line therapy for the treatment of moderate to severe, active rheumatoid arthritis (RA). If licensed, it would offer an additional treatment option for adult patients who have either responded inadequately, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs), and one or more previous tumour necrosis factor alpha (TNF-α) antagonists. Sarilumab does not currently have Marketing Authorisation in the EU for any indication.
RA affects around 1% of the population (over 580,000 people) in England and Wales. The annual incidence of RA is 1.5 per 10,000 in males and 3.6 per 10,000 in females, which equates to approximately 12,000 new diagnoses each year in the UK. Peak age of onset is 40-70 years and the disease is severe in around 15% of patients. It has been estimated that around 10% of patients with RA (approximately 34,600 people) require treatment with biological therapies after the failure of DMARDs. In 2013-14, there were 52,319 admissions for RA in England, resulting in 19,044 bed-days and 53,207 finished consultant episodes.
RA is currently incurable; however, symptoms can usually be managed. The clinical management of RA includes physical therapy, surgical interventions and a range of pharmacological treatments. Sarilumab is currently being evaluated in a phase III trial programme, consisting of seven studies comparing its effects on a range of composite outcomes vs placebo, adalimumab and tocalizumab. Results from these trials are expected in 2015/2016. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000343 Date abstract record published 03/03/2016 |
|
|
|